Meta‐analysis of three‐in‐one single capsule bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori

Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study

(2018) Vincenzo De Francesco et al.   DIGESTIVE AND LIVER DISEASE

P.01.7 EFFICACY OF TREATMENT WITH PYLERA ® IN COMBINATION WITH RANITIDINE ON FIRST-LINE INFECTION HELICOBACTER PYLORI: EXPERIENCE OF A SINGLE CENTER

(2018) A.F. Ciccaglione et al.   DIGESTIVE AND LIVER DISEASE

P.06.29 10 DAY BISMUTH-BASED QUADRUPLE THERAPY FOR HP ERADICATION IN COMPARISON WITH OTHER THERAPIES IN A POPULATION WITH HIGH CLARITHROMYCIN RESISTANCE IN NORTHEAST ITALY

(2018) M. Franceschi et al.   DIGESTIVE AND LIVER DISEASE

P.01.18 A REAL LIFE OBSERVATIONAL STUDY ON THE ERADICATION OF H. PYLORI INFECTION IN PATIENTS NAÏVE TO TREATMENT USING CONCOMITANT THERAPY OR BISMUTH QUADRUPLE THERAPY (THREE-IN-ONE PILL)

(2018) A.G. Gravina et al.   DIGESTIVE AND LIVER DISEASE

Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study

(2018) Antonio Tursi et al.   DIGESTIVE DISEASES

Análisis retrospectivo del uso de la cuádruple terapia con bismuto (Pylera ® ) en la práctica clínica real en España

(2018) Sandra Agudo-Fernández et al.   Gastroenterologia y Hepatologia

Erradicación de la infección por Helicobacter pylori con una nueva terapia cuádruple basada en bismuto en la práctica clínica

(2018) Elena Pérez-Arellano et al.   Gastroenterologia y Hepatologia

The “three-in-one” formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice

(2018) Rocco Maurizio Zagari et al.   HELICOBACTER

New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial

(2018) Yong Xie et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy

(2018) Mahdi Tarhini et al.   MICROBIAL PATHOGENESIS

Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera® ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study

(2017) Enrique Rodríguez de Santiago et al.   HELICOBACTER

Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population

(2017) Stephan Miehlke et al.   HELICOBACTER

Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains

(2017) Giulia Fiorini et al.   HELICOBACTER

IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori

(2016) Javier P. Gisbert et al.   Gastroenterologia y Hepatologia

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults

(2016) Carlo A. Fallone et al.   GASTROENTEROLOGY

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit

(2016) et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains

(2016) Nelly Muller et al.   Clinics and Research in Hepatology and Gastroenterology

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

(2015) I. Thung et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Comparative effectiveness and tolerance of treatments forHelicobacter pylori: systematic review and network meta-analysis

(2015) Bao-Zhu Li et al.   BMJ-British Medical Journal

Comparative effectiveness and tolerance of treatments forHelicobacter pylori: systematic review and network meta-analysis

(2015) Bao-Zhu Li et al.   BMJ-British Medical Journal

Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication ofHelicobacter pylori

(2014) J. C. Delchier et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Greater Than 95% Success with 14-day Bismuth Quadruple Anti-Helicobacter pyloriTherapy: A Pilot Study in US Hispanics

(2012) Cesar O. Salazar et al.   HELICOBACTER

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

(2011) Peter Malfertheiner et al.   LANCET

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

(2010) Andreas Stang   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Helicobacter pylori treatment in the era of increasing antibiotic resistance

(2010) D. Y. Graham et al.   GUT

Cumulative H. pylori Eradication Rates in Clinical Practice by Adopting First and Second-Line Regimens Proposed by the Maastricht III Consensus and a Third-Line Empirical Regimen

(2008) Theodore Rokkas et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies

(2008) Andreas Lundh et al.   BMC Medical Research Methodology